Sobi and Apellis Pharmaceuticals have reported new results from the open-label period of the randomised Phase III VALIANT trial, assessing Aspaveli (pegcetacoplan) in treating C3 glomerulopathy (C3G) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback